Adaptimmune Therapeutics/$ADAPY
-
1D1W1MYTD1Y5YMAX
About Adaptimmune Therapeutics
ADAPTIMMUNE THERAPTCS ADR
Ticker
$ADAPY
Sector
Primary listing
OTC
Employees
506
Headquarters
Website
ADAPY Metrics
BasicAdvanced
$11m
0.42
$0.10
-
-
Price and volume
Market cap
$11m
52-week high
$0.36
Average daily volume
607k
Financial strength
Current ratio
2.038
Quick ratio
1.638
Long term debt to equity
28.628
Total debt to equity
44.049
Interest coverage (TTM)
-8.82%
Profitability
EBITDA (TTM)
-52.819
Gross margin (TTM)
100.00%
Net profit margin (TTM)
425.49%
Operating margin (TTM)
-1,082.41%
Revenue per employee (TTM)
$10,000
Management effectiveness
Return on assets (TTM)
-25.91%
Return on equity (TTM)
-356.05%
Valuation
Price to earnings (TTM)
0.417
Price to revenue (TTM)
1.775
Price to book
0.33
Price to tangible book (TTM)
0.33
Price to free cash flow (TTM)
-0.086
Free cash flow yield (TTM)
-1,163.33%
Free cash flow per share (TTM)
-0.465
Growth
Revenue change (TTM)
-96.67%
Earnings per share change (TTM)
-131.97%
3-year revenue growth (CAGR)
-39.80%
10-year revenue growth (CAGR)
-8.56%
3-year earnings per share growth (CAGR)
-54.62%
10-year earnings per share growth (CAGR)
-19.68%
What the Analysts think about ADAPY
Analyst ratings (Buy, Hold, Sell) for Adaptimmune Therapeutics stock.
ADAPY Financial Performance
Revenues and expenses
ADAPY Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs